Fifth Third Bancorp’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.87M | Buy |
5,921
+420
| +8% | +$99K | ﹤0.01% | 1304 |
|
|
2026
Q1 | $1.1M | Buy |
5,501
+5,349
| +3,519% | +$1.06M | ﹤0.01% | 1578 |
|
|
2025
Q4 | $28.7K | Buy |
152
+7
| +5% | +$1.34K | ﹤0.01% | 1724 |
|
|
2025
Q3 | $25.7K | Buy |
145
+27
| +23% | +$4.01K | ﹤0.01% | 1785 |
|
|
2025
Q2 | $13.4K | Sell |
118
-7
| -6% | -$748 | ﹤0.01% | 1919 |
|
|
2025
Q1 | $13.1K | Buy |
125
+38
| +44% | +$4.3K | ﹤0.01% | 1912 |
|
|
2024
Q4 | $9.32K | Sell |
87
-27
| -24% | -$3.05K | ﹤0.01% | 1997 |
|
|
2024
Q3 | $11.4K | Buy |
114
+5
| +5% | +$503 | ﹤0.01% | 1950 |
|
|
2024
Q2 | $9.18K | Buy |
109
+11
| +11% | +$875 | ﹤0.01% | 1956 |
|
|
2024
Q1 | $7.16K | Hold |
98
| – | – | ﹤0.01% | 1961 |
|
|
2023
Q4 | $7K | Sell |
98
-55
| -36% | -$3.25K | ﹤0.01% | 2076 |
|
|
2023
Q3 | $9.17K | Buy |
153
+25
| +20% | +$1.65K | ﹤0.01% | 1985 |
|
|
2023
Q2 | $9.23K | Buy |
128
+3
| +2% | +$225 | ﹤0.01% | 2003 |
|
|
2023
Q1 | $9.2K | Buy |
125
+52
| +71% | +$3.7K | ﹤0.01% | 2133 |
|
|
2022
Q4 | $4.88K | Buy |
73
+7
| +11% | +$455 | ﹤0.01% | 2216 |
|
|
2022
Q3 | $4K | Sell |
66
-43
| -39% | -$2.53K | ﹤0.01% | 2244 |
|
|
2022
Q2 | $6K | Buy |
109
+29
| +36% | +$1.65K | ﹤0.01% | 2171 |
|
|
2022
Q1 | $6K | Sell |
80
-7,792
| -99% | -$565K | ﹤0.01% | 2245 |
|
|
2021
Q4 | $759K | Buy |
7,872
+7,733
| +5,563% | +$714K | ﹤0.01% | 624 |
|
|
2021
Q3 | $12K | Sell |
139
-238
| -63% | -$18.4K | ﹤0.01% | 1946 |
|
|
2021
Q2 | $31K | Sell |
377
-89
| -19% | -$7.4K | ﹤0.01% | 1637 |
|
|
2021
Q1 | $44K | Sell |
466
-424
| -48% | -$40.1K | ﹤0.01% | 1486 |
|
|
2020
Q4 | $55K | Sell |
890
-4,616
| -84% | -$263K | ﹤0.01% | 1348 |
|
|
2020
Q3 | $327K | Sell |
5,506
-1,978
| -26% | -$135K | ﹤0.01% | 729 |
|
|
2020
Q2 | $522K | Buy |
7,484
+339
| +5% | +$21.5K | ﹤0.01% | 622 |
|
|
2020
Q1 | $324K | Buy |
7,145
+643
| +10% | +$36.4K | ﹤0.01% | 693 |
|
|
2019
Q4 | $423K | Sell |
6,502
-239
| -4% | -$16K | ﹤0.01% | 690 |
|
|
2019
Q3 | $419K | Buy |
6,741
+930
| +16% | +$58.4K | ﹤0.01% | 684 |
|
|
2019
Q2 | $414K | Buy |
5,811
+443
| +8% | +$32.6K | ﹤0.01% | 680 |
|
|
2019
Q1 | $421K | Buy |
5,368
+254
| +5% | +$19.2K | ﹤0.01% | 656 |
|
|
2018
Q4 | $433K | Buy |
5,114
+1,262
| +33% | +$135K | ﹤0.01% | 651 |
|
|
2018
Q3 | $660K | Sell |
3,852
-1,020
| -21% | -$154K | ﹤0.01% | 601 |
|
|
2018
Q2 | $630K | Sell |
4,872
-1,213
| -20% | -$135K | ﹤0.01% | 628 |
|
|
2018
Q1 | $627K | Sell |
6,085
-1,629
| -21% | -$161K | ﹤0.01% | 610 |
|
|
2017
Q4 | $659K | Buy |
7,714
+440
| +6% | +$38.1K | ﹤0.01% | 599 |
|
|
2017
Q3 | $618K | Sell |
7,274
-896
| -11% | -$70.9K | ﹤0.01% | 603 |
|
|
2017
Q2 | $619K | Buy |
8,170
+107
| +1% | +$7.49K | ﹤0.01% | 629 |
|
|
2017
Q1 | $532K | Sell |
8,063
-680
| -8% | -$44.7K | ﹤0.01% | 688 |
|
|
2016
Q4 | $554K | Sell |
8,743
-56
| -0.6% | -$3.53K | ﹤0.01% | 691 |
|
|
2016
Q3 | $560K | Sell |
8,799
-304
| -3% | -$22.3K | ﹤0.01% | 700 |
|
|
2016
Q2 | $677K | Sell |
9,103
-1,478
| -14% | -$110K | 0.01% | 636 |
|
|
2016
Q1 | $707K | Sell |
10,581
-12
| -0.1% | -$729 | 0.01% | 623 |
|
|
2015
Q4 | $716K | Sell |
10,593
-715
| -6% | -$44.1K | 0.01% | 629 |
|
|
2015
Q3 | $604K | Buy |
11,308
+1,071
| +10% | +$65K | 0.01% | 687 |
|
|
2015
Q2 | $644K | Sell |
10,237
-4,386
| -30% | -$239K | 0.01% | 681 |
|
|
2015
Q1 | $703K | Buy |
14,623
+1,551
| +12% | +$59.4K | 0.01% | 666 |
|
|
2014
Q4 | $434K | Buy |
13,072
+3,855
| +42% | +$125K | ﹤0.01% | 758 |
|
|
2014
Q3 | $270K | Sell |
9,217
-484
| -5% | -$16.1K | ﹤0.01% | 886 |
|
|
2014
Q2 | $377K | Buy |
9,701
+6,607
| +214% | +$268K | ﹤0.01% | 818 |
|
|
2014
Q1 | $130K | Buy |
+3,094
| New | +$129K | ﹤0.01% | 1091 |
|
Other funds holding LGND
JT
CAM
Fifth Third Bancorp's LGND Position: Q2 2026 in Review
Fifth Third Bancorp increased its Ligand Pharmaceuticals (LGND) stake by 7.6% in Q2 2026, buying an estimated $99K and bringing the position to 5,921 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1304.
Fifth Third Bancorp first reported a position in LGND in Q1 2014 and has held it in 50 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Fifth Third Bancorp held 5,921 shares of Ligand Pharmaceuticals worth $1.87M as of Q2 2026.
- Fifth Third Bancorp bought 420 Ligand Pharmaceuticals shares in Q2 2026, an estimated $99K.
- Ligand Pharmaceuticals made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #1304 holding.
- Fifth Third Bancorp first reported a position in Ligand Pharmaceuticals in Q1 2014 and has held it in 50 quarters since.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.